Skip to content

A single-center randomized controlled study of antithrombotic therapy after atrial septal defect closure

A single-center randomized controlled study of antithrombotic therapy after atrial septal defect closure

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035713
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?????

Interventions

Group 1:Aspirin 0.1 g / tablet, once a day, 1 tablet each time, clopidogrel 75 mg / tablet, once a day, 1 tablet each time
Group 2:Aspirin, 0.1 g / tablet, once a day, 2 tablets each time

Sponsors

Zhongshan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The informed consent form should be signed; 2. The age should be between 18-75 years old (including 18-75 years old); 3. Atrial septal defect diagnosed by echocardiography of esophageal ultrasound and suitable for interventional treatment; 4. Patients who have successfully completed the interventional therapy.

Exclusion criteria

Exclusion criteria: 1. There was a history of new stroke in recent 3 months; 2. Abnormal coagulation function, active ulcer, active bleeding, infective endocarditis and uncontrollable hypertension (systolic period > 200mmhg or diastolic blood pressure > 120mmhg); 3. Pregnancy; 4. Atrial fibrillation.

Design outcomes

Primary

MeasureTime frame
Area of new cerebral infarction;Adverse events;

Secondary

MeasureTime frame
Symptoms and signs of new cerebral infarction after operation;Neural scale;

Countries

China

Contacts

Public ContactDandan Chen

Zhongshan Hospital Affiliated to Fudan University

chenchendandan@163.com+86 13788926105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026